Bluejay Diagnostics, Inc. has announced an amendment to its Schedule 13G, disclosing that Intracoastal Capital LLC and its affiliates hold a significant stake in the company. This filing, dated November 10, 2026, reveals that the reporting persons beneficially own approximately 4.99% of Bluejay's common stock, which may influence future corporate actions.

Background

Bluejay Diagnostics, Inc. operates within the surgical and medical instruments and apparatus sector, classified under SIC code 3841. The company is publicly traded on the Nasdaq under the ticker BJDX. Recent filings include an 8-K on November 13, 2026, and a 10-Q on November 12, 2026, indicating ongoing regulatory activity.

What the Filing Says

The amended Schedule 13G states, "As of the close of business on September 30, 2026, each of the Reporting Persons may have been deemed to have beneficial ownership of 234,665 shares of Common Stock...representing beneficial ownership of approximately 4.99% of the Common Stock." This reflects a strategic investment by Intracoastal Capital and its affiliates, including Mitchell P. Kopin and Daniel B. Asher.

Impact

This update may affect shareholders and potential investors in Bluejay Diagnostics, as the involvement of Intracoastal Capital could signal a shift in corporate strategy or governance. The medical instruments industry is continuously evolving, and such investments highlight the competitive landscape among companies striving for innovation.

What's Next

The filing does not say what happens next.